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ABSTRACT
Aims To compare clinical status, mother-to-child transmission (MTCT) rates, use of prevention of (PMTCT) inter-
ventions and pregnancy outcomes between HIV-infected injecting drug users (IDUs) and non-IDUs. Design and
setting Prospective cohort study conducted in seven human immunodeﬁciency virus/acquired immune deﬁciency
syndrome (HIV/AIDS) Centres in Ukraine, 2000–10. Participants Pregnant HIV-infected women, identiﬁed before/
during pregnancy or intrapartum, and their live-born infants (n = 6200); 1028 women followed post-partum.
Measurements Maternal and delivery characteristics, PMTCT prophylaxis, MTCT rates, preterm delivery (PTD) and
low birth weight (LBW). Findings Of 6200 women, 1111 (18%) reported current/previous IDU. The proportion of
IDUs diagnosed with HIV before conception increased from 31% in 2000/01 to 60% in 2008/09 (P < 0.01). Among
women with undiagnosed HIV at conception, 20% of IDUs were diagnosed intrapartum versus 4% of non-IDUs
(P < 0.01). At enrolment, 14% of IDUs had severe/advanced HIV symptoms versus 6% of non-IDUs (P < 0.001). IDUs
had higher rates of PTD and LBW infants than non-IDUs, respectively, 16% versus 7% and 22% versus 10%
(P < 0.001).IDUsweremorelikelytoreceivenoneonatalorintrapartumPMTCTprophylaxiscomparedwithnon-IDUs
(OR 2.81, p < 0.001). MTCT rates were 10.8% in IDUs versus 5.9% in non-IDUs; IDUs had increased MTCT risk
(adjusted odds ratio 1.32, P = 0.049). Fewer IDUs with treatment indications received HAART compared with non-
IDUs (58% versus 68%, P = 0.03). Conclusions Pregnant human immunodeﬁciency virus-infected injecting drug
users in Ukraine have worse clinical status, poorer access to prevention of mother-to-child transmission prophylaxis
and highly active antiretroviral therapy, more adverse pregnancy outcomes and higher risk of mother-to-child trans-
mission than non-injecting drug user women.
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INTRODUCTION
Injecting drug use (IDU) accounts for one in three new
human immunodeﬁciency virus (HIV) infections outside
subSaharan Africa [1], and drives the escalating HIV epi-
demic in eastern Europe and Central Asia (EE&CA). In
Ukraine, an estimated 1–2% of the 45.8 million popula-
tion are injecting drug users (IDUs) [2], and the country
has the second largest population of opioid users in
EE&CA [3], although increases in stimulant injecting
have been reported [4,5]. Ukraine has the highest HIV
prevalence in Europe, at 1.63% in 2007 [4]. Sharing of
injecting equipment, front- and back-loading and pur-
chase of syringes pre-ﬁlled with home-made opiates are
believed to have contributed to the explosive spread of
HIVamongIDUs[5–7],withHIVprevalencesof 23–70%
reported in sentinel surveys in cities including Kiev and
Odessa [7–10]. Approximately 25% of IDUs in Ukraine
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compared with males [7,8], reﬂecting more risky inject-
ing practices, including being injected by others [12,13],
and sexual risks, particularly multiple partners (many
also IDUs) and sex work [6,8,13–16].
Low uptake of health services, including antenatal
care (ANC), is a well-recognized problem among female
IDUs [17,18], including those with HIV [19]. In addition
to the risk of neonatal abstinence syndrome (NAS),
infants of IDUs may be at increased risk of preterm deliv-
ery (PTD), intrauterine growth retardation and low birth
weight (LBW) as well as exposure to maternal infections
such as HIV, sexually transmitted infections (STI), hepa-
titis B (HBV) and C virus (HCV) [17,20–22]. In Ukraine,
ANCservicesareprovidedfreeof charge,withmorethan
90% coverage. Infant mortality was 13 per 1000 live
births in 2009 [23]. Routine antenatal HIV screening
was established in Ukraine in 2000: testing takes place at
pregnancy registration, and for women testing negative
repeat testing occurs at approximately 30 weeks gesta-
tion. Rapid intrapartum testing for women without ANC
testing was introduced nationally in 2003. HIV/AIDS
treatment and care services in Ukraine are organized
through a network of regional HIV/AIDS Centres. Sub-
stantial progress has been made in reducing rates of
mother-to-child transmission (MTCT) of HIV in Ukraine
[24].Littleisknownaboutaccessof IDUstopreventionof
MTCT (PMTCT) services or their pregnancy outcomes,
including MTCT, in this setting, although limited data
from western Europe and the Russian Federation have
demonstrated HIV-infected IDUs to be at increased risk
of non-receipt of PMTCT prophylaxis [25–27] and ante-
natal care [19].
Our aim was to compare clinical status, MTCT rates
and risks, use of PMTCT interventions and pregnancy
outcomes between HIV-infected IDUs and non-IDUs
participating in a prospective cohort study of pregnant
HIV-infected women and their children in Ukraine.
METHODS
The European Collaborative Study (ECS) is an ongoing
prospective cohort study established in 1985 in western
Europe, with centres from Ukraine joining in 2000 [28].
The ECS was established to estimate the rate of and risk
factors for MTCT and to investigate the natural history of
vertically acquired HIV infection. Over the intervening
years the objectives have been reﬁned, consistent with
changing management of HIV infection in pregnancy
and the developing HIV epidemic in Europe, with a
current focus on uptake and safety of PMTCT interven-
tions.The ECS is part of EuroCoord, a European network
of HIV/acquired immune deﬁciency syndrome (AIDS)
cohort studies (http://www.eurocoord.net).
Women identiﬁed as HIV-infected before or during
pregnancy, or through intrapartum testing, and deliver-
ing a live-born infant, are eligible to enrol with informed
consent. Seven HIV/AIDS centres in Ukraine participate:
Odessa, Mykolaiv and Simferopol (since January 2000),
Kyiv, Donetsk and Mariupol (since September 2006) [24]
and Kriviy Rig (since September 2008). Data were col-
lected anonymously on study-speciﬁc questionnaires,
using study serial numbers without personal identiﬁers
(linked anonymous data). Information collected included
maternal socio-demographic characteristics (date and
country of birth, age at leaving full-time education,
marital status, ethnicity, history of IDU, timing of last
IDU), HIV-related data [timing of HIV diagnosis, World
Health Organization (WHO) clinical stage, CD4 count,
antenatal antiretroviral use] and delivery and infant
characteristics (date and mode of delivery, birth weight,
head circumference, gestational age, use of intrapartum
and neonatal PMTCT prophylaxis, presence of NAS,
other perinatal problems, HIV infection status). After
delivery, infants are followed-up to establish infec-
tion status, with infected children then followed-up
6-monthly [29]. There is no maternal follow-up after
delivery.
A nested substudy of the ECS was established in
December 2007, with the aim of obtaining longitudinal
information on childbearing HIV-infected women after
delivery in order to investigate the impact of treatment,
coinfection and exposure to abbreviated antenatal
PMTCTprophylaxisonprognosticmarkersof HIVdisease
progression. Five sites of the ECS participate (Odessa,
Kyiv, Donetsk, Mykolaiv and Kriviy Rig) [30], collecting
initial postnatal data approximately 3–6 months after
delivery and follow-up data annually thereafter. With
regard to the ECS, data are linked anonymously. At enrol-
ment, one questionnaire is completed by the woman and
a clinical questionnaire is completed by her physician.
Variables collected include additional information on
pregnancy not available in the ECS (receipt of ANC,
whether or not the pregnancy was planned), socio-
demographic variables (accommodation type, partner’s
HIV infection status, imprisonment history), current
alcohol use, ever/current smoking, information on IDU
(previous/current IDU, IDU partner, use of harm re-
duction services), HCV coinfection, hepatitis B surface
antigen (HBsAg) positivity, STI diagnosis during the
mostrecentpregnancyorpostnatally,WHOclinicalstage
and highly active antiretroviral therapy (HAART). Data
linkage allowed women participating in both studies to
be identiﬁed. Maternal follow-up information was not
addressed in this analysis.
The study population for this analysis was 6200
mother–child pairs in the Ukraine ECS (enrolled up to
February 2010); 447 women with two infants were
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infants. Multiple births (n = 32) were treated as separate
mother–child pairs. By June 2010, 1028 women were
being followed in the postnatal cohort.
Deﬁnitions
IDU history (current or past) was assigned according to
maternal self-report and/or clinical report; six women
without self- or clinical report of IDU delivered infants
with NAS and were included in the IDU group. Women
weredeﬁnedas‘currentIDUs’if IDUwasreportedduring
the current pregnancy and/or if their infant had NAS,
but we considered all women with an IDU history to be
IDUs in recognition that IDU can be a chronic and relaps-
ing condition [31]. In some analyses, women were clas-
siﬁed as never IDUs (no IDU history), past IDUs (IDU
history but not current) and current IDU. Women with
HIV treatment indications were deﬁned as those with
CD4 counts <200 cells/mm3 and/or with WHO stages
3/4 symptoms. PTD was deﬁned as occurring before
37 completed weeks of gestation. Maternal severe or
advanced HIV symptoms were deﬁned as those in WHO
clinical stages 3 or 4. Elective caesarean section (CS)
deliveries were deﬁned as CS deliveries occurring pre-
labour and before rupture of membranes. Time period
was classiﬁed as follows: 2000–01, 2002–03, 2004–05,
2006–07and2008–10.Infantswithpersistenceof anti-
body beyond 18 months of age and/or a positive virologi-
cal marker of infection regardless of age were included as
HIV-infected.If achildwasHIVantibody-negativeandno
virushadbeendetected(s)hewasclassiﬁedasuninfected,
regardless of age.
Data analysis
Univariable comparisons were assessed with the c2 test
for categorical variables. Logistic regression was used to
obtain unadjusted odd ratios (OR), adjusted odds ratios
(AOR) and 95% conﬁdence intervals (CI) in separate
analyses identifying factors associated with non-receipt
of PMTCT prophylaxis, adverse pregnancy outcomes
and MTCT. For the MTCT analysis, available variables
known to be associated with MTCT risk were included
a priori (mode of delivery, preterm delivery, receipt
of PMTCT prophylaxis/treatment) [24,32–36]. For
the other models, all variables univariably signiﬁcant
(P < 0.05) were considered in the multivariable models
and retained based on Akaike’s information criterion.
Statistical analyses were performed with SAS (version
8.02; SAS Institute, Cary, NC, USA).
RESULTS
Of the 6200 women, 1111 (18%) reported current or
previous IDU, of whom 257 (23%) reported or showed
evidence of IDU in pregnancy; 192 (19%) of the 1028
women being followed postnatally reported an IDU
history.The proportion of IDUs enrolling declined signiﬁ-
cantly, from 36% (88 of 245) in 2000/01 to 29% (152 of
530) in 2002/03, 24% (230 of 978) in 2004/05, 17%
(347 of 2055) in 2006/07 and 13% (294 of 2002) in
2008/10 (c2 = 156.6, P < 0.01).
Maternal characteristics, timing of HIV diagnosis
and coinfections
All women were white, and 99% (6159) had been
born in Ukraine. Maternal socio-demographic charac-
teristics are presented in Table 1, comparing women
with and without an IDU history. IDUs were older than
non-IDUs and more likely to report IDU sexual partners,
previous pregnancy and more than one pregnancy
termination (Table 1). IDUs were less likely to have
planned their most recent pregnancy or to have received
ANC compared with non-IDUs (Table 1). High levels
of cigarette smoking were reported by IDU (Table 1),
who reported smoking a median of 20 cigarettes per day
(range 3, 30) compared with 10 (range 2, 25) among
non-IDUs.
HIV diagnosis before pregnancy was more common
among IDUs than non-IDUs (Table 2), with a signiﬁcant
increase over time in proportion of IDUs aware of their
positive HIV status at conception, from 31% (25 of 80)
in 2000/01 to 40% (91 of 230) in 2003/04 and 60%
(177 of 293) in 2008/09 (c2 = 41.0, P < 0.01). Among
women with unknown HIV status at conception, 20%
(116 of 587) of IDUs were diagnosed through intra-
partum testing versus 4% (153 of 3617) of non-IDUs
(c2 = 203.4, P < 0.01). IDUs had considerably worse
HIV clinical and immunological status than non-IDU
with 14% having severe/advanced HIV symptoms versus
6% of non-IDUs. (Table 2).
There was a higher prevalence of HCV seropositivity
(c2 = 187.5, P < 0.001), HBsAg seropositivity (c2 = 6.8,
P = 0.009), chlamydia (c2 = 14.0, P < 0.001) and HSV-2
(c2 = 6.8, P = 0.009) among IDU compared with non-
IDU, although there was no signiﬁcant difference with
respect to syphilis (Fisher’s exact test, P = 0.44) (Fig. 1,
postnatal cohort only). Of note, 23% of women in
the postnatal cohort not reporting IDU were HCV-
seropositive.
Home-made opiates were the predominant injected
drug, used by 99% (190 of 192) of the IDUs in the post-
natal cohort. Overall, 13% (25 of 192) of IDU reported
injectingdrugspostnatallyand60%(74of 123)reported
having a sexual partner currently injecting drugs. Of the
167 women reporting previous but not current IDU, 157
provided the year of most recent use, with a median of
5 years (range 1–19 years) since last use.
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Overall, substantially more IDUs received no antenatal
or intrapartum PMTCT prophylaxis or only single-
dose nevirapine (sdNVP) (Table 2). IDU was associated
signiﬁcantly with non-receipt of antenatal/intrapartum
PMTCT prophylaxis (OR 2.81; 95% CI: 2.23, 3.51;
P < 0.001 compared with non-IDU). In a logistic regres-
sion analysis of non-receipt of prophylaxis, current IDU
was associated with a more than fourfold increased odds
Table 1 Socio-demographic characteristics of human immunodeﬁciency virus (HIV)-infected women with and without injecting
drug use (IDU) history.
ECS cohort (n = 6104)a
IDU Non-IDU c2
n (%) or median (IQR) P-value
n = 1111 n = 4993
Age at delivery (years) 28.1 (24.6, 31.8) 25.5 (22.4, 29.5) P < 0.001
Parity (n = 6084)
0 559 (50.7) 3016 (60.5) 42.1
1 383 (34.7) 1477 (29.7) P < 0.001
2 161 (14.6) 488 (9.8)
Previous pregnancy termination(s) (n = 6086)
0 547 (49.5) 3108 (62.4) 72.7
1 259 (23.4) 1000 (20.1) P < 0.001
2 299 (27.1) 873 (17.5)
Marital status (n = 6095)
Married/cohabiting 792 (71.4) 4200 (84.2) 99.4
Single/divorced/widowed 317 (28.6) 786 (15.8) P < 0.001
Ever had an IDU sex partner (n = 6065)
Yes 595 (54.5) 1261 (25.4) 356.4
No 497 (45.5) 3712 (74.6) P < 0.001
Age when leaving full-time education (n = 3235)
16 years 204 (36.6) 448 (16.7) 122.5
17–18 years 168 (30.1) 844 (31.5) P < 0.001
19 years 186 (33.3) 1385 (51.7)
Postnatal cohort (n = 1028) n = 192 n = 836
History of imprisonment (n = 960)
Yes 38 (20.4) 3 (0.4) 147.2
No 138 (79.6) 771 (99.6) P < 0.001
Current smoking (n = 986)
Yes 178 (93.7) 317 (39.8) 177.8
No 12 (6.3) 479 (60.2) P < 0.001
Previous pregnancy planned (n = 996)
Yes 101 (53.2) 600 (74.4) 33.4
No 89 (46.8) 206 (25.6) P < 0.001
Receipt of ANC in most recent pregnancy (n = 1001)
Yes 159 (82.8) 785 (97.0) 58.4
No 33 (17.2) 24 (3.0) P < 0.001
HIV status of current partner (n = 883)
HIV-positive 82 (50.0) 276 (38.3) 7.6
HIV-negative 33 (20.1) 189 (26.3) P = 0.022
Unknown 49 (29.9) 254 (35.3)
Living situation (n = 975)
Owned house/apartment 136 (71.6) 568 (72.3) 0.4
Parental home 33 (17.4) 123 (15.7) P = 0.82
Other 21 (11.0) 94 (12.0)
a96 women missing data on IDU status. ANC: antenatal care; ECS: European Collaborative Study; IQR: interquartile range.
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history; this declined to 2.75 increased odds after adjust-
ing for confounding factors (Table 3).
There were 557 women with indications for antiret-
roviral treatment for their own health; of note, CD4
counts were available only for 2401 women, reﬂecting
limited laboratory capacity, particularly earlier in the
study. Of these 557 women, 388 (70%) were non-IDUs
and 169 (30%) were IDUs; signiﬁcantly fewer IDUs
received antenatal HAART compared with non-IDUs,
58% (98 of 169) versus 68% (262 of 388) (c2 = 4.68,
P = 0.031), and the difference remained signiﬁcant
when restricting the analysis to exclude women
diagnosed as HIV-infected in the third trimester or at
delivery (90 of 147 versus 244 of 347, c2 = 3.98,
P = 0.049).
Table 2 Maternal human immunodeﬁciency virus (HIV)-related characteristics and prevention of mother-to-child transmission
(PMTCT) use, stratiﬁed by injecting drug use (IDU) status (n = 6104).
IDU Non-IDU c2
n = 1111 n = 4993 P value
n (%) or median (IQR)
Timing of HIV diagnosis (n = 6200)
Pre-pregnancy 524 (47.2) 1376 (27.6) 357.9
1st/2nd trimester 298 (26.8) 2674 (53.6) P < 0.001
3rd trimester 173 (15.6) 790 (15.8)
Intrapartum 116 (10.4) 153 (3.1)
WHO clinical stage (n = 5303)
I or II 840 (85.7) 4046 (93.6) 67.4
III or IV 140 (14.3) 277 (6.4) P < 0.001
CD4 count
a (n = 2401)
<200 cells/mm
3 52 (14.4) 163 (7.0) 19.1
200–349 cells/mm3 80 (22.2) 439 (21.5) P < 0.001
350–499 cells/mm
3 104 (28.9) 573 (28.1)
500 cells/mm
3 124 (34.4) 866 (42.4)
Median 428 (267, 588) 459 (326, 618)
PMTCT prophylaxis—mother
None 136 (12.2) 236 (4.7) 390.4
sdNVP only 295 (26.6) 470 (9.4) P < 0.001
ZDV and sdNVP 275 (24.8) 2232 (44.7)
ZDV 223 (20.1) 1158 (23.2)
HAART 182 (16.4) 897 (18.0)
aFirstmeasurementinpregnancy.IQR:interquartilerange;HAART:highlyactiveantiretroviraltherapy;sdNVP:single-dosenevirapine;ZDV:zidovudine;
WHO: World Health Organization.
78.9% (127/161)
18.5% (30/162)
2.5% (4/157)
38.9% (49/126)
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Figure 1 Prevalence of coinfections in
injecting drug user (IDU) and non-IDU
women (substudy only)
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Overall,52%womendeliveredvaginally(3856of 6089).
The elective CS rate was 24% (263 of 1111) among IDUs
and 34% (1714 of 4991) among non-IDUs (c2 = 47.2,
P < 0.001). IDUs had higher rates of PTD and LBW
infants compared with non-IDUs, with respective PTD
rates of 16% (174 of 1110) and 7% (368 of 4985)
(c2 = 77.5, P < 0.001) and LBW rates of 22% (245 of
1110) and 10% (521 of 4987) (c2 = 111.7, P < 0.001).
Median head circumference at birth for infants of IDUs
was 33 cm [interquartile range (IQR) 32, 34] and 34 cm
[33,35] for other infants. Current IDUs had rates of PTD
and LBW infants of 22% (56 of 257) and 31% (79 of
257), respectively; 159 (62%) of current IDUs had
infants with NAS, this included six women with no clini-
cal or self-report of IDU at enrolment and 38 women
reporting former IDU, all of whom were classifed as
current IDU according to our study deﬁnitions.
Overall, 25% (275 of 1110) IDUs had a PTD and/or a
LBWinfant(‘adversepregnancyoutcome’).IDUwasasso-
ciated signiﬁcantly with adverse pregnancy outcomes in
univariablelogisticregressionanalyses,togetherwithlate
HIVdiagnosis(usedasaproxyfornoorinadequateANC),
having a cohabiting partner/spouse and PMTCT pro-
phylaxis (P < 0.05); there were no signiﬁcant trends in
adverse pregnancy outcomes over calendar time (overall
and among IDUs). The multivariable model (n = 6040),
which included all the above factors, indicated that the
adjusted odds of an IDU having an adverse pregnancy
outcome compared with a non-IDU was 1.84 (95% CI:
1.55, 2.18, P < 0.001). Repeating this analysis, with IDU
re-classiﬁed, past and current IDU were associated with
theoutcome[respectiveAORs1.67(1.38–2.03)and2.38
(1.78–3.9) versus never IDU]; the AOR for past versus
current IDU was 0.70 (95% CI: 0.51, 0.97, P = 0.03).
MTCT
Overall, <1% (n = 61) women breastfed their infants,
eight of whom were IDUs. Unadjusted MTCT rates were
5.9% (205 of 3489, 95% CI: 5.1–6.7) for non-IDUs and
10.8% for IDUs: 10.0% for past IDUs (63 of 629, 95% CI:
7.8–12.6), 13.1% (29 of 221, 95% CI: 9.0–18.3) for
current IDUs and 21.8% (19 of 87, 95% CI: 13.7–32.0)
for IDUs with intrapartum HIV diagnosis. MTCT rates
declined over calendar time among IDUs, from 17.6%
(13 of 74, 95% CI: 9.7–28.1) in 2000–01 to 3.8% (six of
154,95%CI:1.4–8.3)in2008–09andamongnon-IDUs
from11.6%(17of 146,95%CI:6.9–18.0)to2.8%(26of
933, 95% CI: 1.8–4.1) in the same years. In unadjusted
logistic regression, IDU was associated with a nearly
twofold increased risk of MTCT (P < 0.001) (Table 4).
Classifying IDU as current, past and never, the ORs of
MTCT for past IDU and for current IDU versus never
were 1.75 (95% CI: 1.30, 2.36) and 2.43 (1.60, 3.68),
respectively. In multivariable analysis including IDU as
a dichotomous variable (n = 4328), IDUs had a 32%
Table 3 Factors associated with non-receipt of prevention of mother-to-child transmission (PMTCT) prophylaxis.
Odds ratio (95% CI)
Adjusted odds ratio (aOR) (95% CI),
P-value
IDU history
Never 1.00 1.00
Past IDU 2.29 (1.76, 2.97) 1.97 (1.51, 2.58) P < 0.001*
Current IDU 4.81 (3.43, 6.75) 2.75 (1.90, 3.99) P < 0.001*
Late diagnosis of HIV
No 1.00 1.00
Yes 2.92 (2.34, 3.63) 2.37 (1.88, 3.00) P < 0.001
Preterm delivery
No 1.00 1.00
Yes 3.11 (2.39, 4.06) 2.56 (1.95, 3.38) P < 0.001
No cohabiting partner or spouse
No 1.00 1.00
Yes 2.31 (1.84, 2.91) 1.89 (1.44, 2.33) P < 0.001
Time-period
2000–01 1.00 1.00
2002–03 0.27 (0.16, 0.46) 0.27 (0.16, 0.47) P < 0.001
2004–05 0.35 (0.23, 0.54) 0.42 (0.27, 0.67) P < 0.001
2006–07 0.32 (0.21, 0.47) 0.44 (0.29, 0.67) P < 0.001
2008–10 0.23 (0.16, 0.35) 0.37 (0.24, 0.56) P < 0.001
95%CI:95%conﬁdenceinterval;*aORforpastversuscurrentinjectingdruguse(IDU)was0.72(0.48,1.08),P = 0.11.HIV:humanimmunodeﬁciency
virus.
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compared with non-IDU (aOR 1.32) (Table 4). Repeating
this analysis, adjusting for time-period, the AOR for IDU
decreased slightly to 1.28 (95% CI: 0.97, 1.70), associ-
ated with MTCT with borderline statistical signiﬁcance
(P = 0.08).
DISCUSSION
In this Ukrainian cohort, spanning more than 10 years,
just under one-ﬁfth of women were current or past-IDUs.
IDUs had higher prevalence of coinfections, advanced
HIV disease and severe immunosuppression compared
withotherwomen.Onein10IDUsdidnotaccessPMTCT
prophylaxis, mainly because they were diagnosed too
late. Adverse pregnancy outcomes, including PTD and
LBW as well as MTCT, were more frequent in IDUs and
IDU history was associated independently with a 30%
increased MTCT risk.
IDUs are frequently socially marginalized and socio-
economically deprived, and can be hard to reach with
services, including HIV testing. Coverage of IDUs with
HIV testing (in previous 12 months) is an estimated 30%
in Ukraine [37]. More IDUs here knew their HIV-positive
status before pregnancy than non-IDUs (47% versus
28%), probably reﬂecting HIV testing within addiction
services. However, among women with unknown HIV
status at conception, IDUs were more likely to be diag-
nosed late. One in 10 IDUs were diagnosed intrapartum,
with sdNVP the only potential option for PMTCT pro-
phylaxis compared with 3% of other women, reﬂecting
the fact that one in six received no ANC. In a study in
St Petersburg, Russian Federation, two-thirds of women
presenting in labour with unknown HIV status were
IDUs, mostly without ANC [27]; here the equivalent
ﬁgure was 43%. IDU has been identiﬁed previously as a
risk factor for non-receipt of PMTCT prophylaxis in
western Europe [25,26], but not consistently [38].
In unadjusted analyses, IDU was associated with
a twofold increased MTCT risk and IDUs contributed
31% of all vertical transmissions.The main mechanisms
behind the elevated MTCT risk associated with IDUs were
most probably their lower coverage with PMTCT inter-
ventions and higher rate of PTD. Infants of current IDUs
were at greatest risk of MTCT, with a rate of 13.1%. Such
infants were signiﬁcantly more likely to be delivered
preterm than other infants and had a nearly threefold
increased probability of non-receipt of PMTCT prophy-
laxis, resulting in a nearly 2.5-times increased transmis-
sion risk versus never IDUs in unadjusted analyses. The
ﬁnding that current IDUs were at greatest risk of MTCT
underscores the need to strengthen harm reduction in
Ukraine as a key component of the broad PMTCT strat-
egy. IDUs remained associated signiﬁcantly with a 30%
increased MTCT risk in adjusted analysis; this might
be explained by factors including poorer adherence to
prophylaxis/treatment and higher rates of some coinfec-
tions, including HCV [39–43], but we were unable to
explore further due to limited data.
Thetrendof decliningMTCTratesovertimeappliedto
IDUs as well as other women, with both groups having
rates <4% by 2008–09. This is above the target for
‘virtual elimination’ of HIV among infants [44], but is
very encouraging and largely reﬂects the introduction
Table 4 Risk factors associated with mother-to-child transmission (MTCT) of human immunodeﬁciency virus (HIV).
MTCT rate (%) Odds ratio (95% CI) Adjusted odds ratio (95% CI), P-value
IDU history
No 205/3485 (5.9%) 1.00 1.00
Yes 91/843 (10.8%) 1.94 (1.49–2.51) 1.32 (1.00–1.75) P = 0.049
Premature delivery
No 247/3976 (6.2%) 1.00 1.00
Yes 49/352 (13.9%) 2.44 (1.76–3.39) 1.61 (0.13–2.29) P = 0.08
Mode of delivery
Vaginal 223/2676 (8.3%) 1.00 1.00
Emergency CS 10/190 (5.3%) 0.61 (0.32–1.17) 0.69 (0.35–1.34) P = 0.28
Elective CS 63/1462 (4.3%) 0.50 (0.37–0.66) 0.71 (0.18–0.96) P = 0.03
AN/IP PMTCT prophylaxis
None 48/220 (21.8%) 1.00 1.00
sdNVP 81/571 (14.2%) 0.59 (0.40–0.88) 0.61 (0.35–0.91) P = 0.01
ZDV 75/1761 (4.3%) 0.16 (0.11–0.24) 0.21 (0.14–0.31) P < 0.001
ZDV with sdNVP 85/1193 (7.1%) 0.28 (0.19–0.41) 0.36 (0.24–0.54) P < 0.001
HAART 7/583 (1.2%) 0.04 (0.02–0.10) 0.06 (0.02–0.13) P < 0.001
AN: antenatal; IP: intrapartum; 95% CI: 95% conﬁdence interval; CS: caesarean section; IDU: injecting drug use; HAART: highly active antiretroviral
therapy; PMTCT: prevention of mother-to-child transmission; sdNVP: single-dose nevirapine; ZDV: zidovudine.
124 Claire Thorne et al.
© 2011 The Authors, Addiction © 2011 Society for the Study of Addiction Addiction, 107, 118–128of HAART for PMTCT. Challenges remain, however:
although non-receipt of PMTCT prophylaxis declined
signiﬁcantly over time due to scaling-up of the PMTCT
programme in Ukraine, IDUs still had a two- to threefold
increased risk of non-receipt after adjustment for time-
period and other confounding factors, including late HIV
diagnosis and PTD.
NAS, which occurs in approximately 60% of all new-
borns exposed in utero to opiates [45], was identiﬁed in
62% of newborns of current IDUs. Although NAS is easy
to treat with morphine drops, this treatment is not cur-
rently available in Ukraine. Of particular public health
concern is that nearly a third of PTD here were contrib-
uted by IDUs, probably reﬂecting factors including no or
limited ANC, poor nutrition, alcohol use and smoking,
maternal infections, socio-economic factors and direct
effect of illicit drugs [18,31,46,47]. Smoking among
IDUs was nearly universal (94%), and is associated with
more intense NAS [48]. Maternal drug use is associated
with infant abandonment in eastern Europe [49–51],
and we reported recently that infants with NAS in our
cohort were 10 times more likely to be abandoned than
other infants [52].
Problems faced by IDUs in accessing addiction, HIV,
reproductive and other services [18,31,53] reﬂect barri-
ers to service access (including geographical or adminis-
trative barriers and chaotic and/or mobile life-styles), but
may also arise from speciﬁc avoidance of services follow-
ing prior negative/stigmatizing experiences [31,54,55].
Our study population most probably faced a double
stigma, due to their IDU and HIV status, which may
have been compounded by their gender and pregnancy
[56]. The higher rate of pregnancy terminations and
of unplanned pregnancy in IDUs compared with non-
IDUs are consistent with inadequate access to services.
Although the proportions of IDUs and non-IDUs receiv-
ing antenatal HAART were similar, IDUs had worse
health status, and among women with treatment indica-
tions IDUs were signiﬁcantly less likely to receive HAART.
This inequity is consistent with other ﬁndings, demon-
stratingthatIDUsarelesslikelytoreceiveHAARTorstart
HAART later than non-IDUs [42,53,55,57].
A comprehensive package of care for IDUs should
include HIV testing, treatment and care, tuberculosis
(TB) and STI services and harm reduction, including
needle/syringe exchange programmes (NSP) and opioid
agonist maintenance treatment [58]. For female IDUs,
linkages between these services and reproductive health
services, including pregnancy testing, contraception and
PMTCT are very important [58], but frequently weak.
Provision of multi-disciplinary care is particularly chal-
lenginginUkraine,wherethereremainsatraditionalver-
tical health system with few functional linkages between
services. Coverage with NSP was initially low in Ukraine,
with fewer than 10% of IDUs estimated to be reached by
early 2003 [59]; however, recent estimates indicate that
32% of IDUs were reached by preventive interventions in
the previous 12 months in 2008 [27].
Implementation of opioid agonist maintenance treat-
ment for IDUs has also been slow, with methadone main-
tenance not available until mid-2008 [7]; no women in
our postnatal study received methadone (no data in the
ECS). WHO guidelines include a strong recommendation
for provision of such treatment to pregnant IDUs [58],
and the ﬁrst pilot study of methadone maintenance in
pregnant women will soon start in Ukraine. An addi-
tional beneﬁt of a daily intake of methadone is the facili-
tation of close medical monitoring in pregnant drug
addicts.
One of the most effective ways of preventing HIV
infection in infants is to prevent their mothers from
becoming infected in the ﬁrst place. Recent models
suggest that HIV prevalence in Odessa could be reduced
by 41% over the next 5 years if there were a 60% reduc-
tion in unmet need for services, including NSP, opioid
agonist maintenance treatment and antiretroviral
therapy started promptly when indicated [60]. The spe-
ciﬁc barriers that female IDUs face in accessing harm
reduction services and the role these play in their
increased risk of HIV acquisition require further investi-
gation. Prevention of unintended pregnancies in HIV-
infected women is another important approach to
preventing infant infections. Nearly half the IDUs here
hadnotplannedtheirpregnancy,signiﬁcantlymorethan
other women, in a context of low levels of effective family
planning use and identiﬁed considerable unmet need for
contraception [30].
This study is limited by its observational nature and
the potential for confounding. Social desirability bias
may have prevented some women from reporting IDU.
Although our classiﬁcation also used clinical observation
and NAS, up to 40% of infants with fetal exposure to
opiates do not develop NAS. We therefore cannot exclude
the possibility that some IDUs may have been included in
the non-IDU group, underscored by the 22% prevalence
of HCV in the non-IDU group. Our study population lives
in cities with the highest antenatal HIV prevalence in
Ukraine,includingOdessa,KyivandMykolaiv[9],andwe
estimate that approximately 30% of HIV-infected women
delivering in Ukraine are included in our study (1166 of
3649 in 2008) [10]. Our study excluded women termi-
nating their pregnancy and stillbirths; such groups may
include more IDUs than the study population.
Some important successes documented here include
the increasing proportion of IDUs knowing their HIV
status before pregnancy, the declining proportion receiv-
ingnoPMTCTprophylaxisandsubstantiallylowerMTCT
risk in recent years, regardless of IDU status. However,
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comprehensive care to female IDUs, including harm
reduction, family planning and HIV treatment as well
as provision of ANC and PMTCT, with an emphasis on
improving timely access.
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